[1] Kriengkauykiat J,Ito JI,Dadwal SS.Epidemiology and treatment approaches in management of invasive fungal infections[J].Clin Epidemiol,2011,3(1):175-191.
[2] Cornely OA,Aversa F,Cook P,et al.Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy[J].Eur J Haematol,2011,87(4):289-301.
[3] Walsh TJ,Anaissie EJ,Denning DW,et al.Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America[J].Clin Infect Dis,2008,46(3):327-360.
[4] Chaudhary N,Staab JF,Marr KA.Healthy human T-cell responses to Aspergillus fumigatus antigens[J].PLoS One,2010,5(2):389-394.
[5] Shi LN,Li FQ,Lu JF,et al.Immunoproteomics based identification of thioredoxin reductase GliT and novel Aspergillus fumigatus antigens for serologic diagnosis of invasive aspergillosis[J].BMC Microbiol,2012,12(1):11.
[6] Singh B,Oellerich M,Kumar R,et al.Immuno-reactive molecules identified from the secreted proteome of Aspergillus fumigatus[J].J Proteome Res,2010,9(11):5517-5529.
[7] Shi LN,Li FQ,Lu JF,et al.Antibody specific to thioredoxin reductase as a new biomarker for serodiagnosis of invasive aspergillosis in non-neutropenic patients[J].Clin Chim Acta,2012,413(9-10):938-943.
[8] 史利宁,陆静芬,马春芳,等.抗烟曲霉硫氧还蛋白还原酶GliT抗体对侵袭性曲霉病的诊断价值[J].临床检验杂志,2013,31(3):174-177.
[9] Ito JI,Lyons JM,Hong TB,et al.Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f3 protect mice against invasive aspergillosis.Infect Immun[J].Infect Immun,2006,74(9):5075-5084.
[10] Diaz-Arevalo D,Ito JI,Kalkum M.Protective effector cells of the recombinant Asp f3 anti-Aspergillosis vaccine[J].Front Microbiol,2012,3:299.
[11] Bozza S,Clavaud C,Giovannini G,et al.Immune sensing of Aspergillus fumigatus proteins,glycolipids,and polysaccharides and the impact on Th immunity and vaccination[J].J Immunol,2009,183(4):2407-2414. |